https://www.yahoo.com/lifestyle/father-bedbound-by-lyme-disease-is-back-on-his-feet-due-to-a-drug-for-alcoholism-110955745.html
Father bedbound by Lyme disease is back on his feet due to a drug for alcoholism
www.LymeTreatmentReport.com
https://www.yahoo.com/lifestyle/father-bedbound-by-lyme-disease-is-back-on-his-feet-due-to-a-drug-for-alcoholism-110955745.html
Father bedbound by Lyme disease is back on his feet due to a drug for alcoholism
https://clinicaltrials.gov/ct2/show/NCT03891667
Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients will be randomly assigned to one of two groups:
Treatment Group I- patients will receive Disulfiram for 8 weeks
Treatment Group 2 – patients will receive Disulfiram for 4 weeks followed by 4 weeks of placebo.
The dosing starts at 250 mg on day 1, none on day 2, 250 mg on day 3, none on day 4, and then 250 mg x 3 days. If tolerated, the dose is then increased to 500 mg/day.
Primary outcome is at week 10. Patients will be reassessed at week 14.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: This is a placebo-controlled study using matching capsules for disulfiram and placebo. Neither the participant, the care provider, nor the investigator will know the randomized assignment. The research pharmacy and a researcher not involved with this study will keep the code regarding group assignment.
Primary Purpose: Treatment
Official Title: Disulfiram (“Antabuse”): A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Actual Study Start Date : July 31, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : March 31, 2021